BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30262558)

  • 1. Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets.
    Rijkers M; Schmidt D; Lu N; Kramer CSM; Heidt S; Mulder A; Porcelijn L; Claas FHJ; Leebeek FWG; Jansen AJG; Jongerius I; Zeerleder SS; Vidarsson G; Voorberg J; de Haas M
    Haematologica; 2019 Feb; 104(2):403-416. PubMed ID: 30262558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets.
    Van Osch TLJ; Oosterhoff JJ; Bentlage AEH; Nouta J; Koeleman CAM; Geerdes DM; Mok JY; Heidt S; Mulder A; Van Esch WJE; Kapur R; Porcelijn L; Van der Schoot CE; De Haas M; Wuhrer M; Voorberg J; Vidarsson G
    Haematologica; 2022 Oct; 107(10):2432-2444. PubMed ID: 35354253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation.
    Rijkers M; Saris A; Heidt S; Mulder A; Porcelijn L; Claas FHJ; Bierings R; Leebeek FWG; Jansen AJG; Vidarsson G; Voorberg J; de Haas M
    Haematologica; 2018 Oct; 103(10):1741-1752. PubMed ID: 29858387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages.
    van Osch TLJ; Steuten J; Nouta J; Koeleman CAM; Bentlage AEH; Heidt S; Mulder A; Voorberg J; van Ham SM; Wuhrer M; Ten Brinke A; Vidarsson G
    Platelets; 2023 Dec; 34(1):2129604. PubMed ID: 36185007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of platelet aggregation induced by HLA-related antibodies.
    Brandt JT; Julius CJ; Osborne JM; Anderson CL
    Thromb Haemost; 1996 Nov; 76(5):774-9. PubMed ID: 8950789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions.
    van Osch TLJ; Pongracz T; Geerdes DM; Mok JY; van Esch WJE; Voorberg J; Kapur R; Porcelijn L; Kerkhoffs JH; van der Meer PF; van der Schoot CE; de Haas M; Wuhrer M; Vidarsson G
    J Thromb Haemost; 2022 Dec; 20(12):3011-3025. PubMed ID: 36165642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.
    Zhu D; Ravindranath MH; Terasaki PI; Miyazaki T; Pham T; Jucaud V
    Clin Exp Immunol; 2014 Aug; 177(2):464-77. PubMed ID: 24611451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.
    Jackman RP; Lee JH; Pei R; Bolgiano D; Lebedeva M; Slichter SJ; Norris PJ
    Transfusion; 2016 Jun; 56(6):1442-50. PubMed ID: 27079754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential.
    Kushihata F; Watanabe J; Mulder A; Claas F; Scornik JC
    Transplantation; 2004 Oct; 78(7):995-1001. PubMed ID: 15480164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro.
    Wassmuth R; Hauser IA; Schuler K; Erxleben H; Arnold ML; Koelman CA; Claas FH; Kalden JR
    Transplantation; 2001 May; 71(10):1436-42. PubMed ID: 11391232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet alloimmunization after multiple transfusions: a prospective study of 50 patients.
    Godeau B; Fromont P; Seror T; Duedari N; Bierling P
    Br J Haematol; 1992 Jul; 81(3):395-400. PubMed ID: 1390213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet activation induces increased Fc gamma receptor expression.
    McCrae KR; Shattil SJ; Cines DB
    J Immunol; 1990 May; 144(10):3920-7. PubMed ID: 2139675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro fixation of C3d and C5b-9 on platelets by human platelet reactive antibodies.
    Kiefel V; Salama A; Mueller-Eckhardt C
    Blut; 1989 Jan; 58(1):33-7. PubMed ID: 2783867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients.
    Guidicelli G; Anies G; Bachelet T; Dubois V; Moreau JF; Merville P; Couzi L; Taupin JL
    Transpl Immunol; 2013 Dec; 29(1-4):17-21. PubMed ID: 24056164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
    Brubaker DB; Romine M
    Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).
    Boackle RJ; Nguyen QL; Leite RS; Yang X; Vesely J
    Mol Immunol; 2006 Feb; 43(3):236-45. PubMed ID: 16199260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor.
    Fitzgerald JR; Loughman A; Keane F; Brennan M; Knobel M; Higgins J; Visai L; Speziale P; Cox D; Foster TJ
    Mol Microbiol; 2006 Jan; 59(1):212-30. PubMed ID: 16359330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A complement-mediated rat xenotransfusion model of platelet refractoriness.
    Enos AI; Hair PS; Krishna NK; Cunnion KM
    Mol Immunol; 2020 Aug; 124():9-17. PubMed ID: 32485436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.